结肠直肠癌肿瘤疫苗研究现状及展望  

Research status and prospects of colorectal cancer vaccine

作　　者：贾文清(综述) 张弢[1] 赵任(审校)[1] JIA Wenqing;ZHANG Tao;ZHAO Ren(Department of General Surgery,Shanghai Institute of Digestive Surgery,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院普外科,上海市消化外科研究所,上海200025

出　　处：《外科理论与实践》2024年第3期264-269,共6页Journal of Surgery Concepts & Practice

基　　金：国家自然科学基金(82202839);上海申康中心促进市级医院临床技能与临床创新三年行动计划(SHDC2020CR1026B)。

摘　　要：结肠直肠癌(CRC)是全球发病率排名第3、但死亡率排名第2的恶性肿瘤。肿瘤疫苗是一种新型免疫治疗方式,向机体递呈肿瘤抗原,诱导抗肿瘤免疫应答,以形成长期免疫记忆。本文综述不同类型CRC疫苗近5年代表性临床/基础研究进展并展望未来。Colorectal cancer(CRC) ranks in third place in terms of incidence but second in terms of mortality.Cancer vaccine,as a novel immunotherapy,presents tumor antigens to human immune system and further elicits anti-tumor immune response,leading to long-term immune memory.This review summarized representative research progress in both clinical and basic scenario of past five years,and prospected the future of CRC vaccine.

关 键 词：肿瘤疫苗 结肠直肠癌 新生抗原 纳米疫苗 

分 类 号：R735.35[医药卫生—肿瘤] R735.37[医药卫生—临床医学]